<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004237</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067481</org_study_id>
    <secondary_id>RMNHS-TOPIC2</secondary_id>
    <secondary_id>EU-99037</secondary_id>
    <nct_id>NCT00004237</nct_id>
  </id_info>
  <brief_title>Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Navelbine/Epirubicin Versus Navelbine/Mitozantrone Versus Cyclophosphamide/Adriamycin as Preoperative Chemotherapy in Patients With &gt; or = 3cm Diameter Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying three regimens of combination&#xD;
      chemotherapy to compare how well they work in treating women with stage I or stage II breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of vinorelbine/epirubicin and vinorelbine/mitoxantrone in terms&#xD;
           of clinical objective tumor response, clinical complete remission, and pathological&#xD;
           complete remission in women with early stage breast cancer.&#xD;
&#xD;
        -  Compare the efficacy of these 2 new regimens with an established regimen of&#xD;
           cyclophosphamide/doxorubicin in a randomly selected control group of patients.&#xD;
&#xD;
        -  Compare the toxicity and side effects of these 2 new regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to center and age (under 50 vs 50 and over). Patients are randomized to one of&#xD;
      three treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive vinorelbine IV on days 1 and 8 and epirubicin IV on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive vinorelbine IV on days 1 and 8 and mitoxantrone IV on day 1.&#xD;
&#xD;
        -  Arm III: Patients receive doxorubicin IV and cyclophosphamide IV on day 1. Treatment&#xD;
           continues every 3 weeks for 6 courses in the absence of unacceptable toxicity or disease&#xD;
           progression. All patients except those who are under 50 and whose tumors are estrogen&#xD;
           receptor negative receive oral adjuvant tamoxifen daily in addition to chemotherapy.&#xD;
&#xD;
      All patients are offered surgery following completion of chemotherapy. Radiotherapy begins&#xD;
      within 4 weeks of completion of chemotherapy or surgery, whichever is the immediately&#xD;
      preceding treatment.&#xD;
&#xD;
      Patients are followed every 3 months for the first 2 years, every 6 months for the next 3&#xD;
      years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 62-125 patients will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary breast cancer that is potentially operable&#xD;
&#xD;
               -  Synchronous bilateral tumors eligible&#xD;
&#xD;
               -  At least 3 cm in maximum diameter&#xD;
&#xD;
                    -  Tumors at least 2 cm eligible provided primary chemotherapy is deemed&#xD;
                       appropriate and radical surgery would otherwise be required&#xD;
&#xD;
          -  No evidence of metastatic disease&#xD;
&#xD;
          -  No prior breast cancer&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 150,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled angina pectoris&#xD;
&#xD;
          -  No heart failure&#xD;
&#xD;
          -  No clinically significant uncontrolled cardiac arrhythmias&#xD;
&#xD;
          -  LVEF at least 50%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No medical or psychiatric condition that impairs ability to cope physically or&#xD;
             psychologically with the chemotherapy regimen&#xD;
&#xD;
          -  No other serious uncontrolled medical condition&#xD;
&#xD;
          -  No other prior malignancy except basal cell carcinoma of the skin or carcinoma in situ&#xD;
             of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian E. Smith, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

